Finance Associated Press October 27 news (Editor Feng Fang) According to incomplete statistics from the Finance Associated Press, as of the time of publication, 10 A-share listed companies including Huawen Media Group, Ningbo Fangzheng, ST Huawei, Hubei Guangji Pharmaceutical, Nanwei Health, Infotmic Co.,Ltd, Nu'ertai Biology, Humanwell Healthcare, China Harzone Industry Corp., and Jiangsu Sihuan Bioengineering, announced that the company or related parties have been filed. See details below:

▌Due to suspected violations in information disclosure or insider trading, 10 listed companies or related parties were filed this week, with Infotmic Co.,Ltd, a popular chip stock, among them.

From the perspective of the secondary market performance, the stock prices of some listed companies reacted quite strongly. The day after the announcement, Nanwei Health, Nu'ertai Biology, and China Harzone Industry Corp. respectively dropped by 5.53%, 8.11%, and 11.79%.

Huawen Media Group, mainly engaged in cultural and media businesses, announced on October 25 that the company recently received a 'Filing Notice' from the China Securities Regulatory Commission due to suspected violations in information disclosure. The China Securities Regulatory Commission decided to file a case against the company. On the same day, Huawen Media Group also announced that it received a decision from the Intermediate People's Court of Haikou, Hainan Province on October 25, appointing a liquidation team from Huawen Media Group as the company's temporary administrator for pre-reorganization. Earlier on October 21, Huawen Media Group announced that it received a notice from the Haikou Intermediate People's Court and an application from the applicant Sanya Kelly, who applied for the company to be reorganized due to being unable to repay its debts when due. Huawen Media Group experienced 3 consecutive days of limit-up from October 22 to 24. On the evening of October 24, Huawen Media Group issued an announcement on abnormal fluctuations in stock trading, stating that there were no violations of fair disclosure of information found in the self-inspection. Looking back over time, Huawen Media Group has accumulated a maximum increase of 199% in stock price from its low point in June.

Infotmic Co.,Ltd, a SoC chip design company, announced on October 23 that the company received a notice that the relevant personnel of the restructuring were issued a 'Filing Notice' by the China Securities Regulatory Commission for allegedly leaking insider information. The case has not been concluded yet, and there is a potential risk of suspension, termination, or cancellation of this transaction. On October 25, Infotmic Co.,Ltd announced that they originally intended to purchase 49% equity of Huaxin Technology and 49% shares of WORLD STYLE by issuing shares and paying cash, and intended to raise supporting funds from companies such as Shunyuan Qianguan. Due to the 'Filing Notice' issued by the China Securities Regulatory Commission to the relevant personnel of the restructuring for allegedly leaking insider information, which has not been concluded, after friendly negotiations and careful study and argumentation with all parties involved in the transaction, the decision was made to terminate this restructuring. In terms of performance, Infotmic Co.,Ltd incurred a net loss of 36.52 million yuan in the first three quarters. In the secondary market, Infotmic Co.,Ltd has accumulated a maximum increase of 77% from the low point in February to date.

Weight loss drug concept stock Nuotai Biology announced on October 23 that the company and one of the actual controllers, Zhao Dez hong, received a "Notice of Filing" from the China Securities Regulatory Commission, as they are suspected of illegal and irregular disclosure of information, the China Securities Regulatory Commission decided to file a case. According to the company's self-inspection, this case may involve the company's technology transfer related matters for the year 2021. Currently, the company has not received the final investigation conclusion from the China Securities Regulatory Commission, and the operation is normal. According to Nuotai Biology's 2022 annual report, the main ways of technology service transfer include service projects of simple technology development, joint project establishment with subsequent agreement clauses for technology transfer projects, technology service projects of transferring partial or all rights of product listing holders after obtaining approval, involving projects mainly including atorvastatin calcium tablet project, amlodipine atorvastatin calcium tablet project, benzbromarone allopurinol tablet project, and imatinib injection project, etc. In terms of performance, Nuotai Biol ogy achieved a net income of 0.35 billion yuan attributable to shareholders in the first three quarters, a year-on-year increase of 281.9%. In the secondary market, on October 8, Nuotai Biology set a new high for the period, followed by a volatile decline and the next day after receiving the filing notice, intraday trading once approached the 20CM limit down, with the stock price cumulatively dropping by 40% from the high point in October.

Another pharmaceutical stock, Renfu Medicine, announced on October 22 that the company and the controlling shareholder, Dang Dai Technology, received a "Notice of Filing" from the China Securities Regulatory Commission, as they are suspected of illegal and irregular disclosure of information, the China Securities Regulatory Commission decided to file a case against the company and the controlling shareholder. Renfu Medicine announced on the same day that it received an administrative supervisory measure decision from the Hubei Securities Regulatory Bureau. After investigation, the controlling shareholder Dang Dai Technology has unauthorized use of non-operating funds from 2018 to March 2022. As of April 15, 2022, Dang Dai Technology had repaid all principal and interest during the period of use, failed to timely review and disclose related party transactions, failed to timely disclose subsidiary equity information, and had accounting errors in previous financial reports, among other violations. Of note, Renfu Medicine announced on September 30 that the Wuhan Intermediate People's Court ruled on September 30, 2024 to accept the application for the reorganization of Dang Dai Technology by creditors, and designated Wuhan Dang Dai Technology Industrial Group Co., Ltd. Liquidation Group as the administrator of Dang Dai Technology. In the secondary market, Renfu Medicine has cumulatively increased by 51% from the low point in September.